Search
forLearn
5 / 801 resultslearn copper tripeptide-1
learn catalase
learn multipeptides
learn oleanolic acid
Research
5 / 228 results
research 1339 Mature adipocytes inhibit the antimicrobial function of dermal adipogenic stem cells: An explanation for impaired cutaneous defense in obesity
Obesity can weaken the skin's ability to fight infections because fat cells stop and reduce the infection-fighting properties of nearby stem cells.
research Vitamin D receptor-mediated control of Soggy, Wise, and Hairless gene expression in keratinocytes
Vitamin D receptor helps control hair growth genes in skin cells.
research The Epidermal Vitamin D System and Innate Immunity: Some More Light Shed on This Unique Photoendocrine System?
Vitamin D made by the skin plays a role in immune defense and skin health, and more research is needed to understand its full effects.
research Newborn infant skin gene expression: Remarkable differences versus adults
Newborn skin is uniquely prepared to adapt to new environments compared to adult skin.
research Ultraviolet B irradiation increases the expression of inflammatory cytokines in cultured sebocytes
UV-B light increases inflammation-related substances in acne-related skin cells.
Community Join
5 / 1000+ resultscommunity How ET-02 Works. Also no proof that it's better than Minoxidil. At least for now.
ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community Since there is so much hype for cosmeRNA and HMI-115...
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.